1 / 19

Gillian MacLean, Braverman Laboratory McGill University, Department of Human Genetics

Identification of chemical and pharmacological chaperones to treat ZSD patients with the common allele, PEX1-gly843asp. Gillian MacLean, Braverman Laboratory McGill University, Department of Human Genetics GFPD Family & Scientific Conference Lincoln, Nebraska July 28, 2013. Outline.

steffi
Download Presentation

Gillian MacLean, Braverman Laboratory McGill University, Department of Human Genetics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Identification of chemical and pharmacological chaperones to treat ZSD patients with the common allele, PEX1-gly843asp Gillian MacLean, Braverman Laboratory McGill University, Department of Human Genetics GFPD Family & Scientific Conference Lincoln, Nebraska July 28, 2013

  2. Outline • Background • Peroxisome matrix enzyme import • Proteins and impact of genetic changes • PEX1 null and missense mutations • Development of cell based assay • Identification of drugs • chemical, pharmacological, combination therapies • Future directions

  3. Peroxisome Biogenesis Disorders • Zellweger spectrum disorder (ZSD) (~1/60,000) • Zellweger syndrome • Neonatal adrenoleukodystrophy • Infantile refsum disease • Cannot assemble normal peroxisomes • Multiple enzyme deficiencies • Mutations in PEX genes lead to defects in PEX proteins • Broad spectrum  Can relate to which protein is affected and what the mutation is

  4. Pex proteins are involved in peroxisome matrix enzyme import

  5. Protein synthesis depends on DNA sequence • Proteins • Polypeptides comprised of linked of amino acids • Linear sequence gives rise to folded protein • Sequence encoded by DNA • Null allele = • no protein produced • Missense allele = • different amino acid incorporated Nature Education, 2010

  6. Most ZSD mutations are associated with the PEX1 gene • Encodes the PEX1 protein • AAA ATPase (ATPase associated • with diverse cellular activities) • Uses energy from ATP to recycle • PEX5 for additional rounds of import • 60 % of all ZSD alleles • 20% = PEX1-c.2097_2098insT (p.Ile700fs) (null) • 20-30% = PEX1-c.2528G>A (p.Gly843Asp) (missense)

  7. PEX1-Gly843Asp (G843D) • Missense allele • Misfolded protein • Increased degradation • Reduced function • However: • Milder affect on patients • Progressive Aspartate (D) Glycine (G) Non-native Mutation Unfolded protein Native protein Intermediate Arakawa et al. 2006

  8. Cell based assay developed to detect recovery of reporter protein importation • Patient fibroblasts grown in cell culture • expresses “Green Fluorescent Protein” (GFP)-PTS1 reporter • PEX1-G843D/null G843D

  9. Courtesy of Joe Hacia

  10. Functional recovery of peroxisomes observed in treated PEX1-G843D fibroblasts Untreated 30 OC • GFP-PTS1 reporter localizes to the peroxisomes when: • Grown at lower temperatures • Grown with non-specific chemical chaperones 200 mM TMAO 100 mM betaine (Zhang et al., 2010)

  11. Functional recovery suggests improved folding • Decrease temperature • Cells are in lower energy state • Reduced degradation of misfolded proteins • Proteins have more time to find correct conformation • Not applicable for patients • Chemical chaperones • Create environment for better protein folding • Non- specifically enhances protein folding • Requires high concentrations

  12. Assay effectively used for the identification of potential drugs • Screened 2000 small molecule compounds • Identified hit compounds flavonoids No treatment (- ) 10 uM Diosmetin 150 mM Betaine(+)

  13. Testing of additional flavonoids Tested >50 flavonoids Compared import recovery by dose response

  14. Discovery of potential pharmacological chaperones • Pharmacological chaperones: • Interact with proteins selectively -> stabilize or improve folding • May be, or mimic binding partners • Enzyme substrate • Protein ligand • Co-factors • PEX1 is a AAA ATPase • Flavonoids bind ATP bining sites

  15. Potential for combination therapies improve PEX1-G843D folding • Chemical chaperones: • Interact with proteins non-selectively • Betaine • Pharmacological chaperones: • Interact with proteins selectively • Flavonoids • Proteasome inhibitors: • Inhibit degradation of misfolded proteins • Bortezomib PEX1-G843D levels

  16. Combination therapies result in an additive effect • Low doses betaine + flavonoid = more effective than high dose flavonoid

  17. Confirmation of cell-based reporter assay • Evaluate recovery of endogenous matrix enzyme import • Evaluate biochemical parameters • Plasmalogen levels • DHA levels IN PROGRESS

  18. Summary and Future Directions • Effective cell based assay • PEX1-G843D patient cell line • GFP-PTS1 reporter • Demonstrates recovery • Chemical and pharmacological chaperones identified • Shown to work in combination • Great starting point! • Better understand current potential compounds • Develop more sensitive, more general assays • Continue to look for even better compounds • Treat a broader group of patients • Make the best and safest drugs available ASAP!

  19. Acknowledgements • McGill community • Eric Shoubridge and Olga Zurita • Armando Jardim • Murielle Akpa • A special thanks to families and patients for their kind contributions • Nancy Braverman laboratory • Catherine Argyriou • Sara Birjandian and Tara Saberian • Sarn Jiralerspong • Erminia Di Pietro • Claudia Matos-Miranda • Wei Cui • Steve Steinberg and ShandiHiebler • Joe Hacia • Gabrielle Dodt Funding organizations • Woodbury Peroxisome Disease Family Funding

More Related